Vaccine Account Leader for Health Systems & Payers

GSK; United States; Sur place; USD 110 000 - 150 000; Plein temps

Résumé du poste

GlaxoSmithKline is seeking a Vaccine Account Manager to own B2B relationships within large healthcare networks across Kentucky and neighboring states. You will engage senior clinical and non-clinical stakeholders to understand priorities and deliver customized value propositions for vaccine access and formulary success.

The role requires strong account management, contracting knowledge, and collaboration with field teams. Travel up to 40% is expected in designated districts.

Qualifications

• Bachelor’s Degree from an accredited institution.
• Previous vaccines sales experience.
• Combined minimum of 5 years in Pharmaceutical Sales, Marketing, Payer or Business Development.
• Valid driver’s license; no relocation assistance.
• Travel Required: Up to 40% (based on district size).

Responsabilités

• Strategic Account Development and Management with large customers and key decision-makers.
• Achieve or exceed customer-specific sales targets and participate in contracting processes.
• Coordinate with cross-functional teams to support vaccination programs and formulary access.
• Provide clinical education and understanding of vaccine efficacy and safety Profiles.
• Maintain CRM records and complete required training and compliance modules.
• Analyze market trends and formulary landscape to identify growth opportunities.

Connaissances

Account management

Communication

Strategic planning

Influencing

Formation

Bachelor's Degree

Description du poste

GlaxoSmithKline is seeking a Vaccine Account Manager to own B2B relationships within large healthcare networks across Kentucky and neighboring states. You will engage senior clinical and non-clinical stakeholders to understand priorities and deliver customized value propositions for vaccine access and formulary success.

The role requires strong account management, contracting knowledge, and collaboration with field teams. Travel up to 40% is expected in designated districts.